Recombinant human FCGRT is produced by expressing the expression vector that contains the human FCGRT gene segment (24-297aa) and the N-terminal GST-tag gene in E. coli. As confirmed by SDS-PAGE, this high-quality recombinant FCGRT protein achieves over 90% purity and is available in liquid or lyophilized powder forms. Ideal for studies in immunology, this recombinant FCGRT ensures reliable and consistent results for your research needs.
The human FCGRT protein is a critical component of the immune system, primarily involved in transporting and regulating immunoglobulin G (IgG) antibodies. It plays a pivotal role in the transcytosis of maternal IgG across the placenta, facilitating passive immunity from mother to fetus [3][4].
FCGRT operates through a pH-dependent mechanism, exhibiting a high affinity for IgG at acidic pH levels, such as those found in endosomes while releasing IgG at neutral pH, typical of the extracellular environment [3][5]. This property is essential for maintaining serum IgG levels and prolonging the half-life of IgG antibodies in circulation, which is crucial for effective immune responses [2][5]. Additionally, FCGRT is involved in recycling IgG and albumin, contributing to their homeostasis within the body [1][6].
References:
[1] S. Reznik, A. Tiwari, & C. Ashby, Efgartigimod, an fcrn antagonist, as a potential treatment for post covid-19 syndrome, Acta Materia Medica, vol. 2, no. 2, 2023. https://doi.org/10.15212/amm-2023-0004
[2] M. Babamohamadi, Anti-ctla-4 nanobody as a promising approach in cancer immunotherapy, Cell Death and Disease, vol. 15, no. 1, 2024. https://doi.org/10.1038/s41419-023-06391-x
[3] D. Ferguson and J. Blanco, Regulation of the human fc-neonatal receptor alpha-chain gene fcgrt by microrna-3181, Pharmaceutical Research, vol. 35, no. 1, 2018. https://doi.org/10.1007/s11095-017-2294-0
[4] M. Yoshida, K. Kobayashi, T. Kuo, L. Bry, J. Glickman, S. Claypoolet al., Neonatal fc receptor for igg regulates mucosal immune responses to luminal bacteria, Journal of Clinical Investigation, vol. 116, no. 8, p. 2142-2151, 2006. https://doi.org/10.1172/jci27821
[5] M. Pyzik, L. Kozicky, A. Gandhi, & R. Blumberg, The therapeutic age of the neonatal fc receptor, Nature Reviews Immunology, vol. 23, no. 7, p. 415-432, 2023. https://doi.org/10.1038/s41577-022-00821-1
[6] J. Cervenak, B. Bender, Z. Schneider, M. Magna, B. Carstea, K. Liliomet al., Neonatal fcr overexpression boosts humoral immune response in transgenic mice, The Journal of Immunology, vol. 186, no. 2, p. 959-968, 2011. https://doi.org/10.4049/jimmunol.1000353
